Anonymous ID: 182740 Oct. 4, 2026, 6:40 a.m. No.25104259   πŸ—„οΈ.is πŸ”—kun   >>4352

https://www.youtube.com/watch?v=2gIgwoz9_DQ

 

Oh HELL Yeahβ€¦πŸ˜‚πŸ˜‚πŸ˜‚

 

Baher 386

 

386

Dec 19, 2017 6:22:21 PM EST

Q !UW.yye1fxo ID: 03c2f4 No. 127429

Dec 19, 2017 6:21:26 PM EST

Anonymous ID: 836800 No. 127420

>>127397

>>127397

Whistle Blower.. truther.. hero?

>>127420

PATRIOT of the highest caliber.

Q

 

 

Delving into the Anti-Inflammatory Potential of BAY-386: A Technical Guide

 

Quantitative Data on Anti-Inflammatory Effects

The primary evidence for the anti-inflammatory activity of BAY-386 stems from its

demonstrated ability to inhibit the expression of Monocyte Chemoattractant Protein-1 (MCP-1)

and C-X-C Motif Chemokine Ligand 1 (CXCL1) in Human Umbilical Vein Endothelial Cells

(HUVECs). These chemokines are pivotal in the recruitment of monocytes and neutrophils,

respectively, to inflammatory sites.

While specific IC50 values for BAY-386 in these assays are not publicly available in the

immediate search results, the compound has been characterized as a potent antagonist. For

the broader class of PAR-1 antagonists, significant reductions in key inflammatory markers

have been quantified in various studies. For instance, the PAR-1 antagonist vorapaxar has

been shown to significantly reduce levels of pro-inflammatory cytokines and adhesion

molecules.

 

https://pdf.benchchem.com/14758/Delving_into_the_Anti_Inflammatory_Potential_of_BAY_386_A_Technical_Guide.pdf

Anonymous ID: 182740 Oct. 4, 2026, 8:08 a.m. No.25104651   πŸ—„οΈ.is πŸ”—kun   >>4660

>>25104629

Never realized at the time, reporting any child trafficking, specifically regarding state "child Protective Services" who rely on HHS/FED Title IVE funding to the Eff Bee Hive, would not only be ignored, hidden from investigation.

 

Anon now questions this drop meaning.

 

Report to FBI/ DOJ.

Watch what happens.(IGNORED, SWIFTLY RETALIATED AGAINST FOR REPORTING, THATS WHAT THE FUCK HAPPENS)

Spotlight.

Subject deviation.

Risk.

End.

Q